SHENZHEN-WOODY-VAPES
31.5.2022 18:00:06 CEST | Business Wire | Press release
ICCPP launched the full-range ceramic coil solution including disposable ceramic coil at Vaper Expo UK in Birmingham on May 27, 2022 -- a new category empowered by its "Digital Transformation" strategy, marking a new era in the global vape industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220528005017/en/
For the first time, ICCPP exhibited as a group and showcased its branded ODM+ solution and full-range ceramic coil solution. Adopting the Gene Tree technology, ICCPP’s ceramic coil will be integrated with the ODM+ business to promote a greater evolution in the industry. The ceramic coil, ICCPP’s first product released since it jointly launched the digital strategy with SAP and PwC, is bound to become a benchmark in the global vape industry.
Breakthrough: ceramic coil solution for disposable and multiple categories
In the vape industry, the ceramic coil technology is a key indicator of technological advancement of a company. ICCPP began to engage in the ceramic coil technology in 2019 by forming a R&D team led by "Peacock Program" talents, aiming to achieve an industry-leading level with the third or fourth generation of ceramic coil, and fully surpass the peers with the fifth or sixth generation.
Committed to becoming the leader in atomization technology, ICCPP brings a natural and pleasant vaping experience to the customers with its nanocrystalline (NC) materials and technical innovation. From thick film to thin film, from wire heating and surface heating to solid heating, ICCPP’s NC ceramic atomization technology has been constantly optimized the data model of the coil and enhancing the team's R&D strength to address the pain points in the vape coil industry. The newly launched Gene Tree thin film technology features five technical advantages, namely powder-free, improved safety, finer atomization, a longer lifespan, and an improved flavor.
As a result of the continuous endeavor of the R&D team, ICCPP recently launched the new generation of Gene Tree film technology and product applications, which, compared to the third-generation ceramic coil, has improved the flavor, increased the coil lifespan, and improved product reliability, bringing users a natural and pleasant vaping experience.
ICCPP will soon launch a disposable product equipped with the Gene Tree ceramic technology, with such features as longer-lasting flavor, more puffs, better restoration of flavor, and higher reliability, will bring revolutionary user experience, trigger a revolution in the industry, and become an industry milestone.
"Digital + technological innovation " to provide ODM + digital solution
ICCPP’s core advantages at the technical level are derived from its huge investment in scientific and technological innovation. On May 26, ICCPP announced the official launch of the "Digital Transformation Project" at its Shenzhen headquarters, becoming the world's first major company in the vape industry to cooperate with SAP and PwC. This marks that ICCPP will lead the industry into the phase of digital transformation.
The digital strategy refers to the overall digital innovation of the company integrating R&D, manufacturing, export, overseas marketing, etc. In the future, ICCPP will create an unprecedented "digital closed loop" and new digital competitiveness by creating digital R&D, digital manufacturing, digital marketing, and digital consumer experience. The mode of “digital + technological innovation” will become ICCPP’s underlying competitive advantage, including digitization + chips, digitization + fragrance, and digitization + smart manufacturing. "The company will drive development through digitalization and create new value through digitalization." Through digital transformation, the company aims to bring greater contributions to the industry and global consumers.
In order to develop ceramic coil, ICCPP quickly simulated the atomization effect by setting a data model and inputting parameters such as interface and size, so as to find the optimal configuration without sample production, thus accelerating product development and delivery. At present, ICCPP has a set of long-term plans for refillable and disposable ceramic coil products, and has reached cooperation intentions with at least 5 overseas major customers.
Mission of a leading going-out company: to empower global customers with technical innovation
ICCPP knows that customers in this era don’t need the traditional ODM anymore, but the branded ODM+. Therefore, the company has launched the new strategic partnership integrating brand positioning, user insight, product design, product development and after-sales, to guide customers to embrace new era of product customization.
Firstly, ICCPP promises to provide customers with the latest technology applications, and give them the same or even better technology as ICCPP’s own brands. Secondly, ICCPP shares all cutting-edge technologies with the entire industry chain in the strategic cooperation, including labs and institutes, automated factories, overseas user insights and global marketing services. This confidence of ICCPP comes from its rich and successful overseas experience and the ability to provide customers with one-stop services. ICCPP is committed to building two global platforms to empower customers: a truly open, Android-like vape technology platform, and a globalization platform based on years of overseas experience.
As the first strategic category after the digital upgrade, the ceramic coil solution can adapt to the full range of product lines. Emboding the industry's most advanced technologies, it is set to create a new vape category, improve user experience and bring changes to the market structure. On the one hand, ICCPP ODM+ business will undergo the digital upgrade and efficiency upgrade of the whole operation system integrating market survey, R&D, product design, order, delivery, and after-sales; on the other hand, it will establish in-depth cooperation with global customers on the ceramic coil solution. So far, ICCPP has reached cooperation intentions on this ceramic coil technology with many overseas major customers. ICCPP expects to bring more surprises to global customers and restructure the market in future.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220528005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom